O'Neill Gilmore Neil 4

What Happened
Neil O'Neill, CEO and director of Editas Medicine (EDIT), was granted a derivative equity award on March 12, 2026 covering 1,015,200 shares. The grant is reported at $0.00 in the filing (recorded as an award/derivative acquisition), meaning no cash was paid at grant and no immediate sale or exercise occurred.

Key Details

• Transaction date: 2026-03-12; Filing date: 2026-03-16 (filed within required two business days).
• Reported transaction type/code: A (grant/award or other acquisition); amount: 1,015,200 shares; reported price: $0.00.
• Vesting: This option was granted March 12, 2026 and vests over four years in equal monthly installments beginning April 12, 2026 through March 12, 2030 (footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding, cashless exercise, or sale in this filing.

Context
This is a standard executive equity grant (an option award), typically part of compensation and retention programs. It is not a sale or purchase that signals immediate market action — the award vests over time and would only convert into exercisable/owned shares according to the vesting schedule. The filing was timely under SEC Form 4 rules.